Clinical trials: Graft -Versus-host-disease
Tinnitus
The Effect of Gabapentin on the Sensation and Impact of Tinnitus
This study evaluated the effectiveness of gabapentin in treating tinnitus in two populations: Tinnitus with associated acoustic trauma and tinnitus without associated acoustic trauma.
- Trial name
- NCT00257270
- Testing
- gabapentin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tinnitus Research Consortium
Chronic Graft-Versus Host Disease
Treatment of Chronic GVHD of Liver or Lungs by ECP
Chronic graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation and the leading cause of death more than 2 years after transplantation.During the past 30 years survival of…
- Trial name
- NCT00271869
- Testing
- Extracorporeal photoimmunotherapy
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Acute Graft Versus Host Disease, Intestinal Graft Versus Host Disease
Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract
This phase II trial studies how well methylprednisolone sodium succinate works in treating patients with graft-versus-host disease (GVHD) of the gastrointestinal tract that has begun within 100 days of transplant (acute GVHD).
- Trial name
- NCT02425813
- Testing
- Budesonide, Methylprednisolone Sodium Succinate
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Graft Versus Host Disease
Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation
Investigators hypothesize that combination of ATLG with PTCy in matched or mismatched unrelated hematopoietic stem cell transplantation will reduce acute and chronic GVHD incidence.
- Trial name
- NCT03357159
- Testing
- Cyclophosphamide, anti-human T-lymphocyte immunoglobulin (ATLG)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Sheba Medical Center
Graft Versus Host Disease, Acute, Endothelial Dysfunction
Origin of CEC in Patients After Allo-HSCT
We believe that CEC, besides coming from cells shedding from patient vasculature, could partly belong to donor, originating from the cellular graft.
- Conditions
- Graft Versus Host Disease, Acute, Endothelial Dysfunction, Immune Tolerance
- Trial name
- DCEC-PIANO (NCT04038827)
- Testing
- D-CEC counting
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Back Pain, Low
Effects of Mackenzie and Tailored Mat Exercises in Post-Menopausal Women With Low Back Pain
Group A will receive tailored mat exercises. Group B will receive Mckenzie exercises. A baseline treatment including moist hot pack and TENS will be given to both of these groups.
- Trial name
- NCT06750380
- Testing
- Tailored mat exercise program, McKenzie exercises
- Where
- Pakistan
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Acute Graft Versus Host Disease
Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease
In this study, a combination of two T-cell directed antibodies both conjugated to a cell-killing toxin will be evaluated. Previous in vitro studies have demonstrated that this so-called immunotoxin-combination (IT-combination)…
- Trial name
- NCT00640497
- Testing
- IT-Combination
- Where
- 3 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Henogen
Migraine
An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.
The purpose of this study is to assess the long-term safety and effectiveness of topiramate for the prevention of migraine headaches in adults. Topiramate has been approved to prevent migraine headaches in adults.
- Trial name
- NCT00210860
- Testing
- topiramate
- Volunteers
- 142 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Graft Versus Host Disease, Hematopoietic Cell Transplantation Recipient
Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
This pilot clinical trial studies how well a gluten free diet works in preventing graft versus host disease in patients who are undergoing a donor stem cell transplant.
- Trial name
- NCT03102060
- Testing
- Dietary Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rutgers, The State University of New Jersey
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
Phase II trial evaluating the safety \& efficacy of Atorvastatin for prophylaxis of Acute Graft Versus Host Disease (GVHD) in patients with hematological malignances undergoing human leukocyte antigen (HLA)-Matched Related Donor…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01491958
- Testing
- atorvastatin, Tacrolimus, methotrexate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Acute Graft Versus Host Disease
First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)
This study aims to evaluate the optimal dose (Recommended Phase 2 Dose, RP2D), preliminary safety, and efficacy of gecacitinib (also known as jaktinib) in combination with glucocorticoids as first-line therapy for patients with…
- Trial name
- NCT07285889
- Testing
- Gecacitinib (also known as Jaktinib) combined glucocorticoids
- Where
- China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Graft Versus Host Disease, Leukemia
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00608517
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Immune and Microbial Reconstitution, Systemic Viral Infection
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and their donors at the Masonic Cancer Center…
- Conditions
- Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
- Trial name
- NCT03557749
- Testing
- Blood Sample, Stool Sample, Urine Sample
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00096161
- Testing
- Cyclosporine, Mycophenolate Mofetil, Pentostatin
- Where
- 5 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Graft vs. Host Disease
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
To determine whether treatment with ustekinumab will alter the ratio of T Regulatory Cell (Treg)/total cluster of differentiation 4 (CD4)+ cells in peripheral blood at day 30 post-hematopoietic cell transplantation (HCT).
- Trial name
- Ustekinumab (NCT01713400)
- Testing
- Ustekinumab, Tacrolimus (TAC), Sirolimus
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Lymphoma
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn what dose of a kind of immune cell called T-lymphocytes (T-cells) given as a donor infusion about 8-9 weeks after a stem cell transplant has the best results.
- Conditions
- Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
- Trial name
- NCT01518153
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Low Back Pain
Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial
This study is designed to examine brain properties for placebo response in chronic back pain patients. The investigators have preliminary data indicating that, in blinded clinical trial studies with neutral instructions regarding…
- Trial name
- NCT02013427
- Testing
- Naproxen, Omeprazole
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Northwestern University
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
This study involves the use of a drug called Thymoglobulin, which is approved in the USA to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
- Trial name
- NCT00088543
- Testing
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Where
- 14 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Cholelithiasis, Cholecystitis, Acute
Evaluation of Risk Factors Leading to Conversion From Laparoscopic Cholecystectomy to Open Surgery
This retrospective controlled study aims to evaluate risk factors that affect open conversion in laparoscopic cholecystectomy. Patient characteristics, medical history, biochemical and radiological studies of the patient will…
- Conditions
- Cholelithiasis, Cholecystitis, Acute, Cholecystitis, Chronic, Gallbladder Diseases
- Trial name
- NCT06244589
- Testing
- Laparoscopic cholecystectomy, Open-conversion cholecystectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 1,695 people
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.